Core Viewpoint - The company Zhongyuan Xiehe has received approval from the National Medical Products Administration for clinical trials of VUM02 injection for the treatment of severe/critical pneumonia, marking a significant step in the development of a novel cell therapy product [1] Company Summary - The full subsidiary Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd. has been granted a "Drug Clinical Trial Approval Notice" for VUM02 injection [1] - VUM02 injection is derived from umbilical cord mesenchymal stem cells (UC-MSC) obtained from selected healthy newborns, indicating a unique source for the new drug [1] - The total research and development investment for the related project amounts to RMB 16.5624 million [1] Industry Summary - Currently, there are no similar cell therapies approved for the treatment of severe/critical pneumonia globally, highlighting a potential market opportunity for VUM02 injection [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia, marking a significant advancement in the company's product pipeline [1] Company Summary - VUM02 injection is a cryopreserved cell preparation independently developed by Zhongyuan Union, with the clinical indication expanding to include the treatment of severe/critical pneumonia [1] - As of the announcement date, there are no similar cell drugs approved for the treatment of severe/critical pneumonia globally, with the fastest progressing similar drugs still in clinical trial stages [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is an innovative drug developed by the company, derived from umbilical cord mesenchymal stem cells (UC-MSC) [1] - The drug is a cryopreserved cell preparation made from selected healthy newborn umbilical cord tissue, which undergoes in vitro separation, expansion, harvesting, and freezing [1] - The clinical trial aims to expand the indications for VUM02 injection to include the treatment of severe/critical pneumonia [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is an autologous developed cryopreserved cell preparation derived from selected healthy newborn umbilical cord tissue [1] - The clinical indication for VUM02 injection is being expanded to include the treatment of severe/critical pneumonia [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from selected healthy newborn umbilical cord tissue through in vitro separation, expansion, harvesting, and freezing [1] - The clinical indication for VUM02 injection is being expanded to include the treatment of severe/critical pneumonia [1]

Group 1 - The company will participate in the "2025 Tianjin Listed Companies Investor Online Collective Reception Day and Half-Year Performance Briefing" to enhance interaction with investors [1][2] - The event will be held online on September 11, 2025, from 15:00 to 17:00, allowing investors to join via the "Panjing Roadshow" website, WeChat public account, or the Panjing Roadshow APP [1][2] - Key company representatives attending the event include Vice Chairman and General Manager Wang Hongqi, independent directors Hou Xinyi and Luo Mingsheng, and CFO Chen Yiqing [2] Group 2 - The company will address investor concerns regarding its 2025 half-year performance, corporate governance, development strategy, and operational status during the event [2] - The company encourages widespread participation from investors in this interactive session [2]

Group 1 - The company Zhongyuan Qihe announced its participation in the 2025 Tianjin-listed companies investor online reception day and semi-annual performance briefing [2] - The event is scheduled for September 11, 2025 [2]

证券代码：600645 证券简称：中源协和 公告编号：2025-036 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演 APP，参与本次互动交流。活动时间为 2025 年 9 月 11 日（周四）15:00-17:00。 出席本次活动的有公司副董事长、总经理 WANG HONGQI（王洪琦）先生， 独立董事侯欣一先生和罗明生先生，副总经理、财务总监兼董事会秘书陈轶青先 生（如有特殊情况，出席人员会有调整）。届时公司将在线就公司 2025 年半年度 业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 中源协和细胞基因工程股份有限公司 二○二五年九月五日 1 中源协和细胞基因工程股份有限公司 关于参加 2025 年天津辖区上市公司投资者网上集体 接待日暨半年报业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流 ...

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

格隆汇8月27日丨中源协和(600645.SH)发布2025年半年度报告，报告期实现营业收入7.16亿元，同比下 降10.71%；归属上市公司股东的净利润5777.05万元，同比下降32.18%；扣除非经常性损益后的归属于 上市公司股东的净利润5389.17万元，同比下降35.82%；基本每股收益0.13元。 ...